[go: up one dir, main page]

DK0526531T3 - Liposomes with positive excess charge - Google Patents

Liposomes with positive excess charge

Info

Publication number
DK0526531T3
DK0526531T3 DK91908541.5T DK91908541T DK0526531T3 DK 0526531 T3 DK0526531 T3 DK 0526531T3 DK 91908541 T DK91908541 T DK 91908541T DK 0526531 T3 DK0526531 T3 DK 0526531T3
Authority
DK
Denmark
Prior art keywords
liposomes
formula
pnn
gly
excess charge
Prior art date
Application number
DK91908541.5T
Other languages
Danish (da)
Inventor
Hansjoerg Eibl
Petra Kaufmann-Kolle
Clemens Unger
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK0526531T3 publication Critical patent/DK0526531T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

New liposome structures are characterized by having at least 1 mol % of a compound with a positive excess charge having general formula (I), in which R1? represents alkoyl or alkyl mit 14 to 18 C atoms, oleoyl or oleyl; R2? has the same meaning as R1? (although R1? need not be identical to R2?) and furthermore PNN, having formula (a), or Gly, having formula (b), in which A may represent -NH3??+, -NH2?CH3??+, -NH(CH3?)?+2?, N(CH3?)?+3?; R3? represents -O-R1?, -O-PNN, -O-Gly, NH3??+, NH2?CH3??+, NH(CH3?)2??+ or N(CH3?)3??+; R has one of the meanings given for R1?, R2? or R3?; and n is an integer between 0 and 3, preferably 0, provided that the molecule contains one of the above-mentioned groups with a positive charge. Because of their organ-specific behaviour, these liposomes are very useful as excipients in medicinal compositions for treating liver diseases which contain in the disclosed liposomes one or several liver-active substances.
DK91908541.5T 1990-04-27 1991-04-25 Liposomes with positive excess charge DK0526531T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4013632A DE4013632A1 (en) 1990-04-27 1990-04-27 LIPOSOMES WITH POSITIVE EXCESS CHARGE

Publications (1)

Publication Number Publication Date
DK0526531T3 true DK0526531T3 (en) 1994-08-22

Family

ID=6405307

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91908541.5T DK0526531T3 (en) 1990-04-27 1991-04-25 Liposomes with positive excess charge

Country Status (11)

Country Link
EP (1) EP0526531B1 (en)
JP (1) JPH05506661A (en)
AT (1) ATE107503T1 (en)
AU (1) AU643282B2 (en)
CA (1) CA2081119A1 (en)
DE (2) DE4013632A1 (en)
DK (1) DK0526531T3 (en)
ES (1) ES2056648T3 (en)
IE (1) IE62548B1 (en)
PT (1) PT97500B (en)
WO (1) WO1991016880A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH087409B2 (en) * 1988-10-03 1996-01-29 富士写真フイルム株式会社 Processing method of silver halide color photographic light-sensitive material
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE4208527A1 (en) * 1992-03-17 1993-09-23 Max Planck Gesellschaft LIPOSOMES WITH NEGATIVE EXCESS CHARGE
US5552155A (en) * 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
EP0702516A4 (en) 1993-06-01 1998-04-22 Life Technologies Inc Genetic immunization with cationic lipids
EP0638639B1 (en) * 1993-08-10 2000-04-12 Akzo Nobel N.V. Biodegradable fabric softening composition
NZ268146A (en) * 1994-04-12 1997-10-24 Liposome Co Inc Liposome compositions and medicinal uses
US5429755A (en) * 1994-06-16 1995-07-04 Lever Brothers Company Fabric conditioning molecules derived from glycerol and betaine
ES2123307T3 (en) * 1995-02-24 1999-01-01 Kao Corp QUATERNARY AMMONIUM SALT, METHOD FOR THE MANUFACTURE OF THE SAME AND ITS USE AS A SOFTENING COMPOSITION.
EP0863749A2 (en) 1995-11-30 1998-09-16 Vical Incorporated Complex cationic lipids
DE19835611A1 (en) * 1998-08-06 2000-02-10 Max Planck Gesellschaft Novel phospholipids with synthetic, unsaturated alkyl and acyl chains
EP1261620A2 (en) * 2000-02-07 2002-12-04 Roche Diagnostics Corporation Cationic amphiphiles for use in nucleic acid transfection
ITMI20032185A1 (en) * 2003-11-12 2005-05-13 Chemi Spa PROCESS FOR THE SYNTHESIS OF CATIONIC LIPIDS.
DE102004057303A1 (en) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stable crystal modifications of DOTAP chloride
CA2927045A1 (en) * 2006-10-03 2008-04-10 Muthiah Manoharan Lipid containing formulations
NZ605079A (en) * 2010-06-03 2015-08-28 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
ES2562274T3 (en) * 2010-10-06 2016-03-03 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Procedure for the diagnosis, prognosis and treatment of breast cancer metastases
SG194957A1 (en) 2011-05-20 2013-12-30 Merck Patent Gmbh Stable crystal modifications of dotap chloride
JP2013043885A (en) * 2011-08-26 2013-03-04 Kansai Bunri Sogo Gakuen Dehydroamino acid-containing glycerol derivative
CA2856742A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
CN117230193A (en) 2016-05-25 2023-12-15 生物运动有限公司 C-MAF state based therapeutic treatment of breast cancer
EP3713581A1 (en) 2017-11-22 2020-09-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf
KR102054401B1 (en) * 2018-03-26 2019-12-10 주식회사 엔지켐생명과학 1,2-diacylglycerol compound, method for preparing the same and immunomodulating agent including the same as active ingredient
EP4368609A1 (en) * 2022-11-08 2024-05-15 Mello Biotech Taiwan Co., Ltd. Cationic lipids and uses thereof
KR20240174509A (en) 2023-06-07 2024-12-17 포항공과대학교 산학협력단 One-flow synthetic method for synthesizing functional lipid libraries for use in nucleic acid therapeutics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2752553C2 (en) * 1977-11-24 1985-07-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Novel phospholipid-like compounds, their use in the manufacture of plant hybrids and processes for their manufacture
AU5632880A (en) * 1979-04-30 1980-11-06 Brown, G. Convertible sleeping and seating apparatus
DE3374837D1 (en) * 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
ZA8681B (en) * 1985-01-07 1987-08-26 Syntex Inc 1,2-dialkoxy-omega-trialkylammonium cationic surfactants
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
JPS632921A (en) * 1986-06-20 1988-01-07 Yamanouchi Pharmaceut Co Ltd Liposome preparation

Also Published As

Publication number Publication date
ATE107503T1 (en) 1994-07-15
AU7770291A (en) 1991-11-27
WO1991016880A1 (en) 1991-11-14
DE59102030D1 (en) 1994-07-28
IE62548B1 (en) 1995-02-08
EP0526531B1 (en) 1994-06-22
PT97500B (en) 1998-08-31
IE911427A1 (en) 1991-11-06
EP0526531A1 (en) 1993-02-10
DE4013632A1 (en) 1991-10-31
PT97500A (en) 1992-01-31
AU643282B2 (en) 1993-11-11
CA2081119A1 (en) 1991-10-28
JPH05506661A (en) 1993-09-30
ES2056648T3 (en) 1994-10-01

Similar Documents

Publication Publication Date Title
DK0526531T3 (en) Liposomes with positive excess charge
CA2078790A1 (en) 3-benzylidene-1-carbamoyl-2-pyrrolidone analogues
TR200102038T2 (en) Amide components
DE69317413D1 (en) BASIC DERIVATIVES OF GLUTAMIC ACID AND ASPARAGIC ACID AS GASTRINE OR CHOLECYSTOKININE ANTAGONISTS
FI860107A7 (en) AMINOPHENOL DERIVATIVES.
ES8200011A1 (en) Pharmaceutical composition containing a diphenylhydantoin derivative, derivatives used and their preparation.
ES429234A1 (en) N-(1-({107 -phenyl-alkyl)-piperidyl-4)-N-({60 -pyridyl)-carboxylic acid amides and salts thereof
BG104717A (en) Water soluble azoles as broad-spectrum antifungals
DE69311118D1 (en) PHOSPHONO-ARYLETHANOLAMINE COMPOUNDS WITH ANTI-HYPERGLYCEMIC AND / OR ANTIOBESIC EFFECT
ATE232386T1 (en) NEW ENDIYN-QUINONIMINES AND METHOD FOR THE PRODUCTION AND USE THEREOF
FI930171A0 (en) PIPERIDINFOERENINGAR, FRAMSTAELLNING OCH ANVAENDNING AV DESSA
TR200100603T2 (en) Pyrazine compounds
IL125926A0 (en) Compounds related to the amidinium family pharmaceutical compositions containing them and uses thereof
DK640489A (en) C63-AMIDE DERIVATIVES OF 34-DE- (ACETYLGLUCOSAMINYL) -34-DEOXY-TEICOPLANINES
SE7706346L (en) BENZAMINE DERIVATIVES
SE8600046L (en) USE OF AN ESTER SOCIETY THAT TEMPORES BACTERICID AND PRODUCT CONTAINING THE ESTER SOCIETY
SE8303913L (en) Heterocyclic Associations
PT89082A (en) N- (23-VINBLASTINOYLICOS) DERIVATIVES OF 1-AMINO-METHYLPHOSONIC ACID
HUP9803028A2 (en) Cyclic nitrones and pharmaceutical compositions containing them
TR199902433T2 (en) New pyridine derivatives and pharmaceutical compositions containing them.
TR199902092T2 (en) New derivatives of erythromycin, form of preparation, administration as medicine.
EP1056700A4 (en) MEDICINAL USE OF PHENYLALCANOLS AND DERIVATIVES THEREOF
ES451484A1 (en) N-(1,2,4-Triazin-5-on-4-yl)-glycines and herbicidal compositions
IE801354L (en) Piperazino-pyrimido-pyrimidines
AU539986B2 (en) Nitroso-urea compounds + alkylene amine derivatives of ureas